| Texto completo | |
| Autor(es): |
Lara, Leonardo da Silva
[1]
;
Andrade-Lima, Leonardo
[2]
;
Calvet, Claudia Magalhaes
[1]
;
Borsoi, Juliana
[2]
;
Alberto Duque, Thabata Lopes
[3]
;
Henriques-Pons, Andrea
[4]
;
Souza Pereira, Mirian Claudia
[1]
;
Pereira, Lygia Veiga
[2]
Número total de Autores: 8
|
| Afiliação do(s) autor(es): | [1] Fiocruz MS, Inst Oswaldo Cruz, Lab Ultraestrutura Celular, Av Brasil 4365, BR-21045900 Manguinho, RJ - Brazil
[2] Univ Sao Paulo, Inst Biosci, Natl Lab Embryon Stem Cells LaNCE, BR-05508090 Sao Paulo, SP - Brazil
[3] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Celular, Manguinho, RJ - Brazil
[4] Fiocruz MS, Inst Oswaldo Cruz, Lab Inovacoes Terapias Ensino & Bioprod, Av Brasil 4365, BR-21045900 Manguinho, RJ - Brazil
Número total de Afiliações: 4
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Microbes and Infection; v. 20, n. 5, p. 312-316, MAY 2018. |
| Citações Web of Science: | 1 |
| Resumo | |
Chagas disease, caused by Trypanosoma cruzi, is an important global public health problem which, despite partial efficacy of benznidazole (Bz) in acute phase, urgently needs an effective treatment. Cardiotoxicity is a major safety concern for conduction of more accurate preclinical drug screening platforms. Human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CM) are a reliable model to study genetic and infectious cardiac alterations and may improve drug development. Herein, we introduce hiPSC-CM as a suitable model to study T. cruzi heart infection and to predict the safety and efficacy of anti-T. cruzi drugs. (C) 2018 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. (AU) | |
| Processo FAPESP: | 13/08135-2 - CTC - Centro de Terapia Celular |
| Beneficiário: | Dimas Tadeu Covas |
| Modalidade de apoio: | Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs |